Dearborn Partners’s Ascendis Pharma A/S ASND Stock Holding History

Dearborn Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$347K	Hold	1,300	–	–	0.02%	226
2026 Q1	$297K	Hold	1,300	–	–	0.02%	227
2025 Q4	$277K	Hold	1,300	–	–	0.01%	234
2025 Q3	$258K	Hold	1,300	–	–	0.01%	236
2025 Q2	$224K	Hold	1,300	–	–	0.01%	248
2025 Q1	$203K	Buy	+1,300	New	+$186K	0.01%	254

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Dearborn Partners's ASND Position: Q2 2026 in Review

Dearborn Partners held its Ascendis Pharma A/S (ASND) position steady in Q2 2026 at 1,300 shares worth $347K. The position accounts for 0.02% of the portfolio, ranked #226.

Dearborn Partners first reported a position in ASND in Q1 2025 and has held it in 6 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Dearborn Partners held 1,300 shares of Ascendis Pharma A/S worth $347K as of Q2 2026.
Dearborn Partners left its Ascendis Pharma A/S share count unchanged in Q2 2026.
Ascendis Pharma A/S made up 0.02% of Dearborn Partners's portfolio in Q2 2026, its #226 holding.
Dearborn Partners first reported a position in Ascendis Pharma A/S in Q1 2025 and has held it in 6 quarters since.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Dearborn Partners's 13F filing for Q2 2026, filed 13 Aug 2026.